Overview
- Moderna announced a reorganization that gives President Stephen Hoge expanded oversight of R&D, manufacturing and commercial operations to coordinate work across the company’s three franchises.
- The company appointed Ester Banque as chief commercial officer to lead global launch planning and scale a commercial team for up to three planned vaccine rollouts in 2027–2028.
- Regulatory catalysts driving investor interest include a recent EU label for the flu–COVID combination mCOMBRIAX and a U.S. FDA decision date set for the seasonal flu candidate under review.
- Moderna reported first-quarter results that excluded litigation costs, posted $389 million in revenue, reiterated guidance for up to 10% revenue growth in 2026, and has seen its stock rally strongly in 2026.
- The firm is also tracking near-term pivotal clinical readouts in oncology and rare disease that could broaden its commercial portfolio and it will present R&D and platform plans at an upcoming investor event.